Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March. …
Mesoblast updates investors on the succesful US launch of cell medicine
July 20, 2025 Australian Biotech
Latest Video
New Stories
-
BPDInsights one week out with patient voices leading the agenda
May 11, 2026 - - Latest News -
It's mostly a mistake to read too much into a Budget forecast because of what it doesn't include
May 11, 2026 - - Latest News -
Budget silence on HTA Review would confirm what we already know - delayed rollout
May 9, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News